Mazdutide
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Innovent · Phase 2 · Completed · Enrollment 179
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| 3/6 Milligrams (mg) Mazdutide | Obesity or overweight | n/r | n/r | n/r | n/r |
| 10 mg Mazdutide | Obesity or overweight | 10 mg | 32 | n/r | 96.1% at week 32 |
| 16 mg Mazdutide | Obesity or overweight | 16 mg | 32 | n/r | 92.23% at week 32 |
| Placebo | Obesity or overweight | n/r | 32 | n/r | 23.97% at week 32 |
| 3/6 mg Mazdutide | Obesity or overweight | 6 mg | 32 | n/r | 67.64% at week 32 |